Malhotra Ajay, Boltyenkov Artem, Wu Xiao, Matouk Charles C, Forman Howard P, Gandhi Dheeraj, Sanelli Pina
Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA.
Health Economics Modelling, Siemens Healthineers, Manhasset, New York, USA.
World Neurosurg. 2020 Jul;139:e23-e31. doi: 10.1016/j.wneu.2020.02.078. Epub 2020 Feb 24.
Two main techniques for endovascular treatment of patients with acute ischemic stroke are direct aspiration and stent retriever thrombectomy. We hypothesized that the direct aspiration approach would be less costly than the stent retriever approach.
We constructed a decision tree based on the 2 approaches for endovascular treatment. Branch point probabilities were obtained from the best available, recently published literature. Costs were based on the list prices of medical devices from vendors. From this, we obtained a base-case analysis and conducted sensitivity analysis.
Our base-case analysis revealed that the incremental cost per patient for endovascular treatment was $5937 for direct aspiration-first pass technique and $9914 for stent retriever first pass technique. The cost difference per patient treated was $3977. To drive the stent retriever first pass therapy to be the less costly option, the cost of stent retriever first pass technique has to go down more than 50%. Stent retriever first pass carries lower cost when the success rate of first-line aspiration is lower than 14.6%, which is highly improbable. Two-way sensitivity analysis revealed scenarios in which stent retriever first pass approach would be less costly than the direct aspiration-first pass approach; however, conditions required for these scenarios are rarely encountered in clinical practice.
Costs of endovascular treatment using a direct aspiration-first pass approach are less than with a stent retriever first pass approach.
急性缺血性脑卒中患者血管内治疗的两种主要技术是直接抽吸和支架取栓术。我们推测直接抽吸方法的成本低于支架取栓方法。
我们基于这两种血管内治疗方法构建了一个决策树。分支点概率来自现有最佳的近期发表文献。成本基于供应商提供的医疗设备标价。据此,我们进行了基础病例分析并开展了敏感性分析。
我们的基础病例分析显示,血管内治疗每位患者的增量成本,直接抽吸首次通过技术为5937美元,支架取栓首次通过技术为9914美元。每位接受治疗患者的成本差异为3977美元。要使支架取栓首次通过治疗成为成本更低的选择,支架取栓首次通过技术的成本必须降低超过50%。当一线抽吸成功率低于14.6%时,支架取栓首次通过成本更低,但这种情况极不可能发生。双向敏感性分析揭示了支架取栓首次通过方法成本低于直接抽吸首次通过方法的情况;然而,这些情况所需的条件在临床实践中很少遇到。
采用直接抽吸首次通过方法进行血管内治疗的成本低于支架取栓首次通过方法。